Clinical predictors of mortality in patients with pseudomonas aeruginosa infection
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Public Library of Science
Abstract
Background Infections caused by Pseudomonas aeruginosa are difficult to treat with a significant cost and burden. In Lebanon, P. aeruginosa is one of the most common organisms in ventilator-associated pneumonia (VAP). P. aeruginosa has developed widespread resistance to multiple antimicrobial agents such as fluoroquinolones and carbapenems. We aimed at identifying risk factors associated for P. aeruginosa infections as well as identifying independent risk factors for developing septic shock and in-hospital mortality. Methods We used a cross-sectional study design where we included patients with documented P. aeruginosa cultures who developed an infection after obtaining written consent. Two multivariable regression models were used to determine independent predictors of septic shock and mortality. Results During the observed period of 30 months 196 patients were recruited. The most common predisposing factor was antibiotic use for more than 48 hours within 30 days (55%). The prevalence of multi-drug resistant (MDR) P. aeruginosa was 10%. The strongest predictors of mortality were steroid use (aOR = 3.4), respiratory failure (aOR = 7.3), identified respiratory cultures (aOR = 6.0), malignancy (aOR = 9.8), septic shock (aOR = 18.6), and hemodialysis (aOR = 30.9). Conclusion Understanding resistance patterns and risk factors associated with mortality is crucial to personalize treatment based on risk level and to decrease the emerging threat of antimicrobial resistance. © 2023 Frem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Description
Keywords
Anti-bacterial agents, Cross-sectional studies, Drug resistance, multiple, bacterial, Humans, Pneumonia, ventilator-associated, Pseudomonas aeruginosa, Pseudomonas infections, Retrospective studies, Shock, septic, Aztreonam, Carbapenem, Cefepime, Ceftazidime, Cilastatin, Ciprofloxacin, Imipenem, Levofloxacin, Meropenem, Piperacillin plus tazobactam, Quinolone derivative, Steroid, Antiinfective agent, Adult, Adult respiratory distress syndrome, Aged, Antibiotic resistance, Antibiotic sensitivity, Article, Bacteremia, Chemotherapy, Community acquired infection, Controlled study, Cross-sectional study, Diagnostic test accuracy study, Female, Fever, Hemodialysis, Hospital infection, Human, Hypoalbuminemia, In-hospital mortality, Intensive care unit, Major clinical study, Male, Mortality, Multidrug resistance, Pseudomonas infection, Receiver operating characteristic, Recurrent infection, Respiratory failure, Risk factor, Sensitivity and specificity, Sepsis, Septic shock, Urinary tract infection, Ventilator associated pneumonia, Wound care, Retrospective study